Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $9.6 million.

  • Day One Biopharmaceuticals' Share-based Compensation fell 17.25% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $48.3 million for FY2024, which is 22.68% up from last year.
  • Day One Biopharmaceuticals' Share-based Compensation amounted to $9.6 million in Q3 2025, which was down 12.27% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Share-based Compensation ranged from a high of $13.0 million in Q2 2024 and a low of $5.6 million during Q2 2022.
  • Its 3-year average for Share-based Compensation is $11.0 million, with a median of $10.9 million in 2025.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Share-based Compensation surged by 68.30% in 2023, and later dropped by 17.25% in 2025.
  • Day One Biopharmaceuticals' Share-based Compensation (Quarterly) stood at $6.8 million in 2022, then soared by 58.22% to $10.8 million in 2023, then grew by 2.07% to $11.0 million in 2024, then fell by 17.25% to $9.6 million in 2025.
  • Its last three reported values are $9.6 million in Q3 2025, $10.9 million for Q2 2025, and $12.9 million during Q1 2025.